Media Release

ZURICH, SWITZERLAND - JANUARY 7, 2015

Nobel Biocare appoints new Chief Financial Officer

Nobel Biocare announced today that effective February 1, 2015, Mr. Tullio Di Dio will be appointed Chief Financial Officer of Nobel Biocare succeeding Mr. Oliver Walker as he has decided to leave the company to pursue his career interests outside Nobel Biocare.

Mr. Di Dio joins Nobel Biocare with 23 years of finance experience including assignments at United Technologies, Roche and during the past 12 years with Danaher. Most recently, Mr. Di Dio served as Vice President, Finance for Beckman Coulter EMEA. He played an important role in integrating Beckman Coulter into Danaher.

Richard Laube, CEO of Nobel Biocare: "I wish to welcome Tullio Di Dio who will provide valuable experience as Nobel Biocare integrates into Danaher. At the same time, I wish Oliver Walker much success in his new endeavors and would like to thank him for his efforts and contributions in helping to turn Nobel Biocare around and make it a more predictable and performing business during his two and a half years of service. Our finance team has become a significantly more capable and effective organization with his leadership."

Contact information:

Süha Demokan

Investor & Corporate Relations

Tel: +41 43 211 42 30, +41 79 430 81 46

suha.demokan@nobelbiocare.com

Disclaimer

This media release contains forward-looking statements based on beliefs of Nobel Biocare's management. When used in this media release, words such as "anticipate", "believe", "estimate", "expect", "intend", "plan" and "project" are intended to identify forward-looking statements. They may involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of Nobel Biocare as of the date made with respect to future events and are subject to risks and uncertainties. All of these forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. Nobel Biocare disclaims any intention or obligation to update these forward-looking statements.


Media Release (PDF)



Provider
 Channel
 Contact
Tensid Ltd., Switzerland
www.tensid.ch


 newsbox.ch
www.newsbox.ch


 Provider/Channel related enquiries
marco@tensid.ch
+41 41 763 00 50